<DOC>
	<DOCNO>NCT00322400</DOCNO>
	<brief_summary>This open-label , dose-finding , multi-center study design determine safety maximum tolerate dose AMG 706 give daily combination either weekly paclitaxel ( Arm A ) once-every-3 week docetaxel ( Arm B ) subject locally recurrent metastatic breast cancer . Secondarily , study evaluate pharmacokinetic ( PK ) profile AMG 706 treatment arm , PK profile paclitaxel Arm A PK profile docetaxel Arm B. Additionally , study assess objective tumor response duration response . Exploratory endpoint include investigation potential biomarker development ass effect genetic variation drug metabolism gene , cancer gene drug target gene subject response AMG 706 combination paclitaxel docetaxel .</brief_summary>
	<brief_title>Phase1b Evaluate Safety AMG706 Combination With Paclitaxel Docetaxel Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma breast locally recurrent metastatic disease . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Female 18 year age old . Adequate hematologic , renal hepatic function . Competent comprehend , sign , date IRBapproved inform consent form . Subjects childbearing potential sexually active must provide negative pregnancy test use accept effective method contraception . Prior taxanecontaining treatment within 6 month prior enrollment . Prior treatment include chemotherapy and/or endocrine therapy discontinue &lt; 21 day prior enrollment . More one prior systemic chemotherapy locally recurrent metastatic breast cancer . Current prior history central nervous system metastasis . History arterial venous thrombosis within 1 year prior enrollment . History bleed diathesis bleeding within 14 day prior enrollment . Radiation therapy significant portion bone marrow prior history highdose chemotherapy require bone marrow stem cell support . Hypersensitivity paclitaxel , docetaxel , drug use vehicle cremophor . Prior VEGFr target therapy within 30 day enrollment . Any anticoagulant therapy within 7 day prior enrollment , except warfarin le 2mg per day . Clinically significant cardiac disease include myocardial infarction cardiovascular related event within 1 year enrollment . Uncontrolled hypertension ( systolic &gt; 150 mmHg ; diastolic &gt; 90 mmHg ) . Known HIV positive , hepatitis C positive hepatitis B surface antigen positive . Prior bevacizumab trastuzumab therapy within 12 week enrollment . Nonhealing wound , ulcer fracture . Known history prior episodes cholecystitis , prior biliary procedure prior ongoing biliary disease . Unable take oral medication . Not recover previous therapy . Major surgery within 28 day prior enrollment . Prior malignancy unless treat curative intent without evidence disease great 3 year enrollment . Peripheral neuropathy grade &gt; 1 per CTCAE version 3.0</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Clinical trial</keyword>
	<keyword>AMG 706</keyword>
	<keyword>Anti-angiogenesis</keyword>
	<keyword>Locally Recurrent</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>VEGF</keyword>
	<keyword>Angiogenesis Inhibitor</keyword>
	<keyword>Oral</keyword>
	<keyword>Multi-kinase Inhibitor</keyword>
	<keyword>Anti-tumor</keyword>
	<keyword>PDGF receptor</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Targeted Therapy</keyword>
	<keyword>Oncology</keyword>
	<keyword>Amgen</keyword>
	<keyword>c-Kit</keyword>
</DOC>